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SUMMARY Up to 150 words summarising the case presentation and outcome 
 
We present a case of a 44 year-old male civil servant who presented to the Emergency 
Department following an episode of collapse. He was usually fit and well and whilst at work 
he had developed a headache with pins and needles over his face and subsequently 
collapsed. On arrival to ED, he had a GCS of 4/15. There was no history of note apart from 
being prescribed citalopram for depression. Laboratory investigations revealed severe 
hypophosphataemia (phosphate 0.19mmol/L) and no other electrolyte abnormality. He was 
commenced on intravenous phosphate and his GCS improved to 15 within four hours. 
Further investigations revealed no cause for his severe hypophosphataemia and repeat 
bloods in clinic follow-up showed a normal phosphate level.  
 
BACKGROUND  
 
Collapse is one of the commonest presenting complaints during the acute medical take, and 
is typically a consequence of cardiac or neurological disturbance. Despite the common nature 
of this complaint, it is often challenging to diagnose the cause of collapse in some patients.  
 
Electrolyte disorders can affect cardiac and neurological function, resulting in collapse. 
Electrolyte disorders known to cause collapse include hypocalcaemia (1), hypercalcaemia 
(2), hypokalaemia (3), hyperkalaemia (4), hyponatraemia (5) and hypernatraemia (6). 
However, hypophosphataemia is not commonly associated with collapse; although previous 
reports associate hypophosphataemia with acute confusion (7), visual hallucinations (8) and 
Wernicke’s encephalopathy (9). Hypophosphataemia has also been associated with seizures 
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(10) and coma (11), though importantly these cases were also associated with re-feeding 
and alcohol abuse, respectively.  
 
In this case report, we describe a patient who presented with collapse caused by severe 
hypophosphataemia with no other significant co-morbidity. 
 
CASE PRESENTATION Presenting features, medical/social/family history 
 
A 44-year-old gentleman who worked for the DVLA presented to the Emergency Department 
(ED) with a collapse. He was normally fit and well and was prescribed citalopram for 
depression. He did not smoke or drink alcohol and took no illicit drugs. He had developed a 
headache associated with pins and needles over his face and left arm whilst at work, and 
subsequently collapsed. When the paramedics arrived, he had a GCS of 15, blood pressure 
144/78, capillary blood glucose 11.8mmol/L and was afebrile. 
 
On arrival to the ED his GCS had dropped to 4/15. Other than his reduced GCS, the physical 
examination was unremarkable and there were no signs of neck rigidity or rash. 
 
INVESTIGATIONS If relevant 
 
His admission ECG showed normal sinus rhythm. The full blood count and electrolytes were 
normal. His bone profile demonstrated a calcium level of 2.51mmol/L (normal range 2.20-
2.60mmol/L) and a magnesium level of 0.77mmol/L (normal range 0.70-1.00mmol/L). The 
only biochemical abnormality found was a low serum phosphate of 0.19mmol/L (normal 
range 0.80-1.50nmol/L). During the admission, five days following replacement of his serum 
phosphate, his urinary phosphate level was noted to be normal. A CT head taken on 
admission was also unremarkable. 
 
Further investigations including serum parathyroid hormone, vitamin D, immunoglobulins, 
anti-TTG antibodies. Echocardiogram showed no evidence of LV dysfunction or valvular 
disturbance. Figure 1 demonstrates his serum phosphate level from hospital admission to 
clinic follow-up. 
 
DIFFERENTIAL DIAGNOSIS If relevant 
 
The differential diagnosis included: 
 Possible seizure with a prodromal episode of pins and needles over the body.   
 Possible encephalitis, given his sudden history of collapse and reduced GCS.  
 Cardiac syncope should also be considered, though this young adult and ECG 
demonstrating normal sinus rhythm and a normal QTc. 
 
TREATMENT If relevant  
 
He was commenced on a 500ml intravenous infusion of phosphate polyfusor over 12 hours. 
By the next day his phosphate had increased from 0.19mmol/L to 1.13mmol/L. Whilst 
having this infusion, his GCS improved to 15 within 4 hours and he remained alert 
throughout the remainder of the admission. During his admission to hospital, he underwent 
further testing including Holter monitoring which showed sinus rhythm and an 
echocardiogram demonstrating good ventricular function with an ejection fraction of 55%.  
His biochemical markers were within normal limits, and his serum phosphate was measured 
daily. By day four of his hospital admission, he was started on oral Phosphate Sandoz as his 
phosphate decreased to 0.75mmol/L and had returned to normal three days afterwards. The 
cause of his hypophosphataemia remains unknown. 
 
OUTCOME AND FOLLOW-UP   
 
After 8 days of admission, he was discharged from hospital with a serum phosphate of 
1.22mmol/L. He was followed up in the Endocrine clinic 4 weeks later with repeat blood tests 
which were within normal limits. His phosphate level since the admission has been within 
normal limits with no subsequent re-admission. The cause of his hypophosphataemia 
remains unknown. There was no evidence of re-feeding syndrome or alcoholism and his 
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further biochemical investigations remained normal.  
 
DISCUSSION including very brief review of similar published cases (how many 
similar cases have been published?)  
 
Hypophosphataemia is a relatively common electrolyte disturbance in certain sub-groups, 
prevalent in up to 3.1% of hospital inpatients, up to 33.9% of patients admitted to intensive 
care units, up to 30.4% with chronic alcoholism and up to 80% of septic patients (12). Mild 
(0.65-0.79mmol/L) and moderate (0.32-0.64mmol/L) hypophosphataemia may present with 
non-specific symptoms such as generalised muscle weakness, myalgia and fatigue. Patients 
with severe hypophosphataemia (<0.32mmol/L) may present with serious sequelae such as 
confusion, hallucinations and seizures. As a result of its non-specific symptoms, this 
electrolyte disturbance is often not considered and the patient’s symptoms subsequently 
misdiagnosed (13). 
 
The treatment of hypophosphataemia can be achieved with oral, intravenous or intradialytic 
therapy. The treatment approach is determined by the serum phosphate level and the 
patient’s symptoms. Generally, oral replacement would best be given to those with mild to 
moderate symptoms and levels of hypophosphataemia, whilst patients with severely low 
phosphate and/or symptoms, or who are unable to take phosphate orally would receive 
intravenous replacement. It is important to closely monitor the patient, as intravenous 
phosphate administration can provoke ECG changes, seizures, life-threatening 
hypocalcaemia and hyperkalaemia (13). 
 
There are many causes of hypophosphataemia, including malnutrition (refeeding syndrome, 
anorexia nervosa, malabsorption, alcohol abuse), endocrine (hyperparathyroidism), renal (X-
linked hypophosphatemia, hereditary hypophosphatemic rickets, Fanconi syndrome), 
respiratory alkalosis (sepsis, salicylate poisoning, anxiety) and medications (cisplatin, 
tetracyclines, aminoglycosides, antiretrovirals) (13). Rarely, hypophosphataemia is caused 
by oncogenic osteomalacia, in which elevated serum fibroblast growth factor 23 (FGF 23) 
levels induce hypophosphataemia by binding proximal tubule cells, thereby reducing renal 
phosphate reabsorption (14). Typically, this results from tumours of the bone or soft tissue 
which secrete FGF 23, causing elevated serum FGF 23 levels and subsequent 
hypophosphataemia by renal wasting (15). Typically, this disease presents insidiously with 
progressive weakness, bone and muscle pain and fractures (16). This was not tested for in 
this patient, which is beyond the scope of routine investigation of hypophosphataemia in this 
setting. However, it should be considered in patients who present with such biochemical 
findings and a history of non-specific symptoms such as weakness, generalised pain or 
recurrent fractures, and investigated by testing serum FGF 23 levels.  
 
As shown in previously published cases of patients presenting with acute and severe 
hypophosphataemia, it is often difficult to establish the cause of hypophosphataemia in 
patients and the cause often remains unknown (7). 
 
This case highlights the need for a comprehensive history, examination and biochemistry in 
the assessment of patients who present to ED with collapse, as such electrolyte disorders are 
easily reversible. Subsequent work-up to determine the cause of hypophosphataemia should 
also occur to prevent recurrence and to permit treatment of the underlying disorder. 
 
LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points 
 
 Hypophosphataemia causes collapse, and should be excluded at clinical presentation. 
 Intravenous phosphate should be used to treat patients with severe 
hypophosphataemia and reduced consciousness. 
 It is important to consider the underlying cause of hypophosphataemia to prevent 
recurrence. 
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Figure captions 
 
Figure 1 demonstrates the patient’s serum phosphate level from admission to clinic follow-up 
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